Congress is putting psychedelic therapy for military veterans under a formal spotlight this week, and the testimony already filed for the hearing tells a clear story: the Department of Veterans Affairs is building the machinery to deliver these treatments if regulators approve them, while insisting that safety, evidence and readiness have to come first.
The hearing, titled “Psychedelic-Assisted Therapies for Veterans: The Path Forward,” is scheduled before the House Veterans’ Affairs Subcommittee on Health on Wednesday, November 18, 2026, at 2:15 p.m. in 360 Cannon House Office Building, according to the committee calendar. Rep. Mariannette Miller-Meeks chairs the Health Subcommittee and Rep. Julia Brownley is its ranking member, according to Legis1’s preview of the panel. VA officials are set to testify alongside medical professionals and researchers, Marijuana Moment reported.
That combination matters. This is not a hearing about legalization, and none of the prepared testimony frames it that way. It is a hearing about whether a federal health system that treats millions of veterans can be ready — clinically, ethically and operationally — if a psychedelic therapy crosses the line from investigational research to approved care.
What The VA Says It Is Doing Now
Andrew Gradison, a senior advisor to the under secretary for health at the VA’s Veterans Health Administration, said in written testimony posted by the panel that the administration “has taken decisive action to accelerate psychedelic research and eliminate regulatory obstacles that have historically slowed progress.” He cited an executive order President Donald Trump signed in April aimed at expediting psychedelic therapy access, describing it in his testimony as the “first EO in American history dedicated specifically to accelerating clinical research and regulatory review of psychedelics.”
The numbers in that testimony show how far the research effort has moved. Gradison said VA is now conducting 21 active clinical studies on psychedelics to treat mental health conditions, and he pointed specifically to a trial VA announced in August to investigate whether psilocybin can help veterans struggling with treatment-resistant depression. VA’s own announcement of that trial, called PIVOT, fills in the design: it is a randomized, controlled study enrolling veterans diagnosed with treatment-resistant major depressive disorder, with or without concurrent post-traumatic stress disorder, comparing outcomes between two psilocybin dosage levels at five locations — Birmingham and Tuscaloosa in Alabama, Portland in Oregon, Philadelphia, and Seattle. VA said the trial uses pharmaceutical-grade drugs in a safe, controlled clinical setting, with safety protocols developed with the Food and Drug Administration and psychological support included.
Gradison also pointed to a memorandum of understanding VA signed with the Department of Health and Human Services in July outlining a partnership to collaborate on research and development of psychedelic medicines, an agreement he said “lays the groundwork for unprecedented VA-HHS operational cooperation on psychedelic trials.” Separately, HHS said on November 12 that it would put up to $4.9 million over five years through ARPA-H into research on ibogaine as a possible treatment for PTSD, according to Legis1 — a reminder that the hearing lands days after a new federal funding announcement in the same field, not in isolation.
Readiness, Not Just Research
The most consequential part of Gradison’s testimony may be what VA says it is preparing for next. He said the department has already identified 10 facilities “with the expertise, physical space, and operational capacity needed to serve as early implementers, educators, or sites-in-training,” with teams experienced in psychedelic research protocols preparing to translate that experience into clinical care if treatments are approved.
He anchored that preparation in three priorities: “first, ensuring Veteran safety above all else; second, building a rigorous body of evidence to determine which treatments work for which Veterans; and third, laying the foundation so that, pending all regulatory approvals, VA is positioned to be the first health care system in the Nation to deliver these treatments to Veterans.”
That is an ambitious claim, and the other witnesses filed testimony that reads, in large part, as a check on it. Leith States, a former HHS acting assistant secretary for health who now runs the consulting firm States Strategies, is calling on Congress to support research that “answers the clinical questions veterans and clinicians face,” while requiring VA to set and track milestones for clinical readiness and access and holding the department accountable for patient safety and lasting improvement in veterans’ lives. “Doing our duty means investigating promising treatments with urgency and discipline, speaking plainly about what we know, and preparing the people and systems needed to deliver responsible, safe, and ethical care,” his testimony said.
Marion Coe of Pinney Associates, whose testimony references work compiling responses to a request for information issued by the bipartisan Congressional Psychedelics Advancing Therapies (PATH) Caucus, emphasized that VA must “begin preparing its clinical infrastructure and workforce” before FDA approval of any psychedelic treatments “if it is to be ready to expand access as rapidly and as safely possible.” “The central challenge is not simply whether these medicines can work,” Coe said. “It is whether we can build the infrastructure necessary to deliver them safely, ethically, and to the veterans who need them.”
The Hard Scientific Questions Stay On The Table
Not every witness is focused on systems. Mark Niciu, an assistant professor at the University of Iowa, used his testimony to explain research addressing what he called the “major hurdle” of functional unblinding in psychedelic research — the problem that participants and evaluators can often tell who received the drug and who received a control, because the effects are acute and intense. “Expectancy bias is particularly salient in psychedelic medicine trials,” he said, warning that when a psychedelic is compared with an inert or insufficiently matched placebo, both parties can immediately and accurately know their assignment, potentially affecting the rest of the trial. It is a methodological caution that goes to the heart of how much weight any single positive result can carry.
Raquel Halfond, senior director of evidence-based practice and health equity at the American Psychological Association, emphasized transparency and accountability, infrastructure, associated therapy and workforce demands in her testimony. The association “encourages VA and all federal partners to adopt a stepped, interdisciplinary care model” following rigorous and ethical research, she said, with national minimum competencies, independent medical and psychological assessments, strong ethical safeguards and informed consent, on-site human monitoring, structured follow-up and drug-specific staffing requirements. “Each of these areas is necessary to make veteran protection and safety the utmost priority,” she said.
Gradison, for his part, emphasized that VA discourages self-medicating with psychedelics or using them to replace other mental health treatment options — a position VA also stated plainly in its August trial announcement, which noted that clinical use of these therapies outside research will only be considered once FDA approval is granted.
While not testifying in person, Disabled American Veterans, Veterans of Foreign Wars, Special Forces Foundation and Mindbloom all submitted written statements for the record, Marijuana Moment reported.
What Wednesday’s hearing can and cannot do is worth stating plainly. It cannot approve a drug, fund a clinic or change a veteran’s treatment plan. What it can do is put the VA’s readiness claims, its 21 active studies and its 10 early-implementer sites on the congressional record, alongside independent warnings about trial design, workforce and safeguards — and force the department to say, in public, how it will know when the evidence is strong enough to move. For veterans whose conditions have not responded to available treatments, that record is not a cure. It is, for now, the path forward the hearing’s title promises, tested in the open.
Source: Marijuana Moment; House Committee on Veterans’ Affairs calendar; Legis1; U.S. Department of Veterans Affairs (VA News)
The post Congress Turns To Psychedelic Therapy For Veterans As VA Prepares For A Decision It Has Not Yet Made appeared first on The Hype Magazine.

1 day ago
2
